@article{1fbe1c747c3a4e0eb5acfbd9b215795a,
title = "Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab",
keywords = "LONG-TERM EFFECTIVENESS, MAINTENANCE THERAPY, MULTICENTER COHORT, INDUCTION, SAFETY, IMPACT",
author = "Biemans, {Vince B. C.} and {van der Woude}, {C. Janneke} and Gerard Dijkstra and {van der Meulen-de Jong}, {Andrea E.} and Bas Oldenburg and {de Boer}, {Nanne K.} and Mark Loewenberg and Nidhi Srivastava and Bodelier, {Alexander G. L.} and West, {Rachel L.} and Jansen, {Jeroen M.} and {de Vries}, {Annemarie C.} and Haans, {Jeoffrey J. L.} and {de Jong}, {Dirk J.} and Pierik, {Marie J.} and Frank Hoentjen and {Dutch Initiative Crohn and Colitis}",
year = "2020",
month = may,
doi = "10.1002/cpt.1712",
language = "English",
volume = "107",
pages = "1189--1199",
journal = "Clinical Pharmacology & Therapeutics",
issn = "0009-9236",
publisher = "Wiley",
number = "5",
}